Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Polypoidal Choroidal Vasculopathy Choroid Diseases Choroidal Neovascularization Eye Diseases Metaplasia Neovascularization, Pathologic Pathologic Processes Pathological Conditions, Signs and Symptoms Uveal Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Surugadai Nihon university hospital

1-8-13 Kandasurugadai Chiyoda-ku, Tokyo, 101-8309, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of Polypoidal choroidal vasculopathy
must have injection of Ranibizumab

Exclusion criteria

Treatment and study plan

Primary outcomes

Association of Complement Factor H and ARMS2 Genotypes with Response of Polypoidal Choroidal Vasuculopathy to Intravitral Ranibizumab

Time frame: a month after injection

Sponsors and collaborators

Lead sponsor

Nihon University

Other

Registry information

Official study title

Association of Complement Factor H and ARMS2 Genotypes With Response of Polypoidal Choroidal Vasculopathy to Intravitreal Ranibizumab

Important dates

Study start: 2008
Primary completion: 2010
Study completion: 2010
First posted: Jan 6, 2011
Registry last updated: Jan 6, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed